Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research
- Author
- POLHEMUS, Mark E1 2 ; MAGILL, Alan J1 ; ROBINSON, Sally A1 ; HAYNES, John D1 ; STEWART, V. Ann1 ; WARE, Lisa A1 ; BRANDO, Clara1 ; KRZYCH, Urszula1 ; BOWDEN, Robert A1 ; COHEN, Joe D4 ; DUBOIS, Marie-Claude4 ; OFORI-ANYINAM, Opokua4 ; CUMMINGS, James F1 ; DE-KOCK, Els4 ; RIPLEY BALLOU, W4 ; HEPPNER, D. Gray1 ; KESTER, Kent E1 ; OCKENHOUSE, Chris F1 ; LANAR, David E1 ; DUTTA, Sheetij1 ; BARBOSA, Arnoldo1 ; SOISSON, Lorraine3 ; DIGGS, Carter L3
[1] Welter Reed Army Institute of Research (WRAIR), Silver Spring, MD, United States
[2] United States Army Medical Research Unit, Nairobi, Kenya
[3] U.S. Agency for International Development, Washington, DC, United States
[4] GlaxoSmithKline Biologicals, Rixensart, Belgium - Source
Vaccine. 2007, Vol 25, Num 21, pp 4203-4212, 10 p ; ref : 37 ref
- CODEN
- VACCDE
- ISSN
- 0264-410X
- Scientific domain
- Biotechnology; Immunology, immunopathology, allergology; Microbiology, infectious diseases; Virology
- Publisher
- Elsevier, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- AS02A Apical membrane antigen FMP2.1 Falciparum Growth inhibition assay Malaria Processing inhibition assay Recombinant protein Vaccine
- Keyword (fr)
- Adjuvant immunologique Adulte Antigène Immunogénicité Paludisme Plasmodium falciparum Protéine membranaire Protéine recombinante Toxicité Vaccin Apicomplexa Homme Infection Parasitose Protozoa Protozoose
- Keyword (en)
- Immunological adjuvant Adult Antigen Immunogenicity Malaria Plasmodium falciparum Membrane protein Recombinant protein Toxicity Vaccine Apicomplexa Human Infection Parasitosis Protozoa Protozoal disease
- Keyword (es)
- Coadyuvante inmunológico Adulto Antígeno Inmunogenicidad Paludismo Plasmodium falciparum Proteína membranar Proteína recombinante Toxicidad Vacuna Apicomplexa Hombre Infección Parasitosis Protozoa Protozoosis
- Classification
- Pascal
- 002 Biological and medical sciences / 002A Fundamental and applied biological sciences. Psychology / 002A05 Microbiology / 002A05F Applied microbiology / 002A05F04 Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05E Parasitic diseases / 002B05E02 Protozoal diseases / 002B05E02B Human protozoal diseases / 002B05E02B4 Malaria
- Discipline
- Infectious pathology Microbiology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 18752536
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/j.vaccine.2007.03.012 
https://dx.doi.org/10.1016/j.vaccine.2007.03.012
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2007.03.012\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:214:\"Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-na\u00efve adults at the Walter Reed Army Institute of Research\";s:9:\"\u0000*\u0000jtitle\";s:7:\"Vaccine\";s:9:\"\u0000*\u0000stitle\";s:7:\"Vaccine\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:2:\"21\";s:8:\"\u0000*\u0000spage\";s:4:\"4203\";s:8:\"\u0000*\u0000epage\";s:4:\"4212\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0264-410X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"POLHEMUS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Mark E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:22:{i:0;s:14:\"MAGILL, Alan J\";i:1;s:17:\"ROBINSON, Sally A\";i:2;s:14:\"HAYNES, John D\";i:3;s:15:\"STEWART, V. Ann\";i:4;s:12:\"WARE, Lisa A\";i:5;s:13:\"BRANDO, Clara\";i:6;s:15:\"KRZYCH, Urszula\";i:7;s:16:\"BOWDEN, Robert A\";i:8;s:12:\"COHEN, Joe D\";i:9;s:20:\"DUBOIS, Marie-Claude\";i:10;s:21:\"OFORI-ANYINAM, Opokua\";i:11;s:17:\"CUMMINGS, James F\";i:12;s:12:\"DE-KOCK, Els\";i:13;s:16:\"RIPLEY BALLOU, W\";i:14;s:16:\"HEPPNER, D. Gray\";i:15;s:14:\"KESTER, Kent E\";i:16;s:19:\"OCKENHOUSE, Chris F\";i:17;s:14:\"LANAR, David E\";i:18;s:14:\"DUTTA, Sheetij\";i:19;s:16:\"BARBOSA, Arnoldo\";i:20;s:17:\"SOISSON, Lorraine\";i:21;s:15:\"DIGGS, Carter L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"VACCDE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:214:\"Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-na\u00efve adults at the Walter Reed Army Institute of Research\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2007.03.012\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:214:\"Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-na\u00efve adults at the Walter Reed Army Institute of Research\";s:9:\"\u0000*\u0000jtitle\";s:7:\"Vaccine\";s:9:\"\u0000*\u0000stitle\";s:7:\"Vaccine\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:2:\"21\";s:8:\"\u0000*\u0000spage\";s:4:\"4203\";s:8:\"\u0000*\u0000epage\";s:4:\"4212\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0264-410X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"POLHEMUS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Mark E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:22:{i:0;s:14:\"MAGILL, Alan J\";i:1;s:17:\"ROBINSON, Sally A\";i:2;s:14:\"HAYNES, John D\";i:3;s:15:\"STEWART, V. Ann\";i:4;s:12:\"WARE, Lisa A\";i:5;s:13:\"BRANDO, Clara\";i:6;s:15:\"KRZYCH, Urszula\";i:7;s:16:\"BOWDEN, Robert A\";i:8;s:12:\"COHEN, Joe D\";i:9;s:20:\"DUBOIS, Marie-Claude\";i:10;s:21:\"OFORI-ANYINAM, Opokua\";i:11;s:17:\"CUMMINGS, James F\";i:12;s:12:\"DE-KOCK, Els\";i:13;s:16:\"RIPLEY BALLOU, W\";i:14;s:16:\"HEPPNER, D. Gray\";i:15;s:14:\"KESTER, Kent E\";i:16;s:19:\"OCKENHOUSE, Chris F\";i:17;s:14:\"LANAR, David E\";i:18;s:14:\"DUTTA, Sheetij\";i:19;s:16:\"BARBOSA, Arnoldo\";i:20;s:17:\"SOISSON, Lorraine\";i:21;s:15:\"DIGGS, Carter L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"VACCDE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:214:\"Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-na\u00efve adults at the Walter Reed Army Institute of Research\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2007.03.012\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2007.03.012\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:214:\"Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-na\u00efve adults at the Walter Reed Army Institute of Research\";s:9:\"\u0000*\u0000jtitle\";s:7:\"Vaccine\";s:9:\"\u0000*\u0000stitle\";s:7:\"Vaccine\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:2:\"21\";s:8:\"\u0000*\u0000spage\";s:4:\"4203\";s:8:\"\u0000*\u0000epage\";s:4:\"4212\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0264-410X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"POLHEMUS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Mark E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:22:{i:0;s:14:\"MAGILL, Alan J\";i:1;s:17:\"ROBINSON, Sally A\";i:2;s:14:\"HAYNES, John D\";i:3;s:15:\"STEWART, V. Ann\";i:4;s:12:\"WARE, Lisa A\";i:5;s:13:\"BRANDO, Clara\";i:6;s:15:\"KRZYCH, Urszula\";i:7;s:16:\"BOWDEN, Robert A\";i:8;s:12:\"COHEN, Joe D\";i:9;s:20:\"DUBOIS, Marie-Claude\";i:10;s:21:\"OFORI-ANYINAM, Opokua\";i:11;s:17:\"CUMMINGS, James F\";i:12;s:12:\"DE-KOCK, Els\";i:13;s:16:\"RIPLEY BALLOU, W\";i:14;s:16:\"HEPPNER, D. Gray\";i:15;s:14:\"KESTER, Kent E\";i:16;s:19:\"OCKENHOUSE, Chris F\";i:17;s:14:\"LANAR, David E\";i:18;s:14:\"DUTTA, Sheetij\";i:19;s:16:\"BARBOSA, Arnoldo\";i:20;s:17:\"SOISSON, Lorraine\";i:21;s:15:\"DIGGS, Carter L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"VACCDE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:214:\"Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-na\u00efve adults at the Walter Reed Army Institute of Research\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2007.03.012\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:214:\"Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-na\u00efve adults at the Walter Reed Army Institute of Research\";s:9:\"\u0000*\u0000jtitle\";s:7:\"Vaccine\";s:9:\"\u0000*\u0000stitle\";s:7:\"Vaccine\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:2:\"21\";s:8:\"\u0000*\u0000spage\";s:4:\"4203\";s:8:\"\u0000*\u0000epage\";s:4:\"4212\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0264-410X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"POLHEMUS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Mark E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:22:{i:0;s:14:\"MAGILL, Alan J\";i:1;s:17:\"ROBINSON, Sally A\";i:2;s:14:\"HAYNES, John D\";i:3;s:15:\"STEWART, V. Ann\";i:4;s:12:\"WARE, Lisa A\";i:5;s:13:\"BRANDO, Clara\";i:6;s:15:\"KRZYCH, Urszula\";i:7;s:16:\"BOWDEN, Robert A\";i:8;s:12:\"COHEN, Joe D\";i:9;s:20:\"DUBOIS, Marie-Claude\";i:10;s:21:\"OFORI-ANYINAM, Opokua\";i:11;s:17:\"CUMMINGS, James F\";i:12;s:12:\"DE-KOCK, Els\";i:13;s:16:\"RIPLEY BALLOU, W\";i:14;s:16:\"HEPPNER, D. Gray\";i:15;s:14:\"KESTER, Kent E\";i:16;s:19:\"OCKENHOUSE, Chris F\";i:17;s:14:\"LANAR, David E\";i:18;s:14:\"DUTTA, Sheetij\";i:19;s:16:\"BARBOSA, Arnoldo\";i:20;s:17:\"SOISSON, Lorraine\";i:21;s:15:\"DIGGS, Carter L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"VACCDE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:214:\"Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-na\u00efve adults at the Walter Reed Army Institute of Research\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.vaccine.2007.03.012\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:214:\"Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-na\u00efve adults at the Walter Reed Army Institute of Research\";s:9:\"\u0000*\u0000jtitle\";s:7:\"Vaccine\";s:9:\"\u0000*\u0000stitle\";s:7:\"Vaccine\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:2:\"21\";s:8:\"\u0000*\u0000spage\";s:4:\"4203\";s:8:\"\u0000*\u0000epage\";s:4:\"4212\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0264-410X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"POLHEMUS\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Mark E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:22:{i:0;s:14:\"MAGILL, Alan J\";i:1;s:17:\"ROBINSON, Sally A\";i:2;s:14:\"HAYNES, John D\";i:3;s:15:\"STEWART, V. Ann\";i:4;s:12:\"WARE, Lisa A\";i:5;s:13:\"BRANDO, Clara\";i:6;s:15:\"KRZYCH, Urszula\";i:7;s:16:\"BOWDEN, Robert A\";i:8;s:12:\"COHEN, Joe D\";i:9;s:20:\"DUBOIS, Marie-Claude\";i:10;s:21:\"OFORI-ANYINAM, Opokua\";i:11;s:17:\"CUMMINGS, James F\";i:12;s:12:\"DE-KOCK, Els\";i:13;s:16:\"RIPLEY BALLOU, W\";i:14;s:16:\"HEPPNER, D. Gray\";i:15;s:14:\"KESTER, Kent E\";i:16;s:19:\"OCKENHOUSE, Chris F\";i:17;s:14:\"LANAR, David E\";i:18;s:14:\"DUTTA, Sheetij\";i:19;s:16:\"BARBOSA, Arnoldo\";i:20;s:17:\"SOISSON, Lorraine\";i:21;s:15:\"DIGGS, Carter L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"VACCDE\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:214:\"Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-na\u00efve adults at the Walter Reed Army Institute of Research\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
